Drugs / BCG strain Connaught
BCG strain Connaught
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00396370 | Dec 2008 → Jul 2012 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG strain Connaught | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00396370 ↗ |
| Known as | Bacillus Calmette-Guerin | “Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10\^5 CFU vaccine for intradermal administration.” NCT00396370 ↗ |
| Known as | BCG | “Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10\^5 CFU vaccine for intradermal administration.” NCT00396370 ↗ |
| Modality | Vaccine | “8-32 x 10\^5 CFU vaccine” NCT00396370 ↗ |